Arcus Biosciences (RCUS) Change in Account Payables (2017 - 2026)

Arcus Biosciences' Change in Account Payables history runs 10 years deep, the most recent figure standing at -$3.0 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 200.0% year-over-year to -$3.0 million; the TTM figure through Mar 2026 stood at $18.0 million (up 157.14% YoY), while the FY2025 annual figure was $24.0 million, up 700.0% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$3.0 million, down from $13.0 million in the prior quarter.
• The five-year high for Change in Account Payables was $13.0 million in Q3 2025, with the low at -$19.0 million in Q2 2023.
• The 5-year median for Change in Account Payables is $4.0 million (2022), against an average of $2.1 million.
• The sharpest annual moves came in 2022 and 2023: Change in Account Payables jumped 1786.79% in 2022, then plunged 575.0% in 2023.
• Arcus Biosciences' Change in Account Payables stood at $8.0 million in 2022, then slumped by 75.0% to $2.0 million in 2023, then soared by 150.0% to $5.0 million in 2024, then jumped by 160.0% to $13.0 million in 2025, then sank by 123.08% to -$3.0 million in 2026.
• Business Quant data shows RCUS's Change in Account Payables at -$3.0 million in Q1 2026, $13.0 million in Q3 2025, and $8.0 million in Q2 2025.